Your browser is looking a little out of date...

To get the best possible experience using our website, we recommend that you upgrade to latest version of this browser or install another web browser. See our Browser Support/Compatibility page for supported browsers list.

Fighting Sickle Cell Disease with Gene Correction Technology

Thursday, November 16 @ 2-3pm ET

Sickle cell disease is a monogenic blood disease, and is the most common serious blood disease in the world affecting 4.4 million people who have SCD, while an additional 43 million have sickle-cell trait as of 2015. Join Mark DeWitt of the Innovative Genomics Institute at UC Berkeley who is part of the team helping to develop a clinical protocol to correct the sickle cell disease mutation using CRISPR /Cas9 in hematopoietic stem cells.

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.